Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dolby Laboratories, Inc. (NYSE: DLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports, quarterly updates, proxy materials, and current reports on material events. As a Delaware corporation with Class A common stock listed on the New York Stock Exchange, Dolby files documents such as Form 10-K, Form 10-Q, Form 8-K, and the Definitive Proxy Statement (DEF 14A) with the U.S. Securities and Exchange Commission.
Dolby’s filings offer detailed insight into its licensing-focused business model, which centers on technologies like Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and related audio and imaging intellectual property. In its proxy statement and other filings, the company discusses its single reportable segment, the importance of royalty-based revenue, and the role of cinema hardware and premium cinema technologies in its overall revenue mix.
Through current reports on Form 8-K, Dolby discloses financial results, dividends, and executive compensation plans. These filings cover quarterly and annual revenue, net income, non-GAAP metrics, and capital return actions such as cash dividends on Class A and Class B common stock. They also describe executive bonus plans that tie incentive payouts to non-GAAP operating income, revenue, and other performance metrics.
The Definitive Proxy Statement (DEF 14A) provides information on corporate governance and executive compensation, including proposals for the election of directors, advisory votes on named executive officer compensation, and ratification of the independent registered public accounting firm. It also summarizes non-GAAP financial measures and includes reconciliations to GAAP in appendices.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, highlight key figures and themes, and make it easier to understand Dolby’s financial condition, risk disclosures, and governance practices. Investors can use this page to follow Dolby’s official communications to regulators, monitor dividend and capital allocation decisions, and review the frameworks used to evaluate and reward the company’s leadership.
Kevin J. Yeaman, President and CEO and director of Dolby Laboratories (DLB), reported option exercise and an immediate sale of shares on 08/12/2025. He exercised an employee stock option to acquire 25,000 shares of Class A common stock at an exercise price of $45.50 per share and simultaneously sold 25,000 shares at a weighted-average sale price of $72.3131 per share. Following these transactions, the reporting person beneficially owns 139,725 shares of Class A common stock indirectly through the Kevin and Rachel Yeaman Family Trust; this total includes 127,735 shares underlying restricted stock units that remain subject to forfeiture until they vest. The filing also notes the exercised option was part of a larger grant covering 194,399 shares, and the sold shares were transacted in multiple sales at prices ranging from $71.63 to $72.59.
Dolby Laboratories (DLB) Form 144 shows a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on 08/12/2025 with an aggregate market value of $1,807,827.50. The filing lists 95,844,185 shares outstanding, and the securities were acquired the same day by stock option exercise with payment in cash. The notice also records multiple recent sales by Yeaman Family Trust between 06/10/2025 and 07/16/2025 in several tranches. By signing, the seller represents they are not aware of any undisclosed material adverse information; a Rule 10b5-1 plan date is not indicated.
Dolby Laboratories (NYSE:DLB) CEO Kevin Yeaman filed a Form 4 for transactions on 06/24/2025.
- Exercised 25,000 options at $45.50.
- Immediately sold the same 25,000 Class A shares at a weighted-average $74.02, generating ≈$1.85 million in gross proceeds.
- Sale represents about 18 % of the shares held in his family trust.
- Post-trade holdings: 114,725 Class A shares (trust), 127,735 unvested RSUs, and 135,615 unexercised options.
The trades were executed under a Rule 10b5-1 plan; no additional corporate events were disclosed.
Dolby Laboratories (DLB) insider filing reports planned sale of 25,000 shares of common stock with an aggregate market value of $1,850,530. The securities were acquired through a stock option exercise on June 24, 2025, and are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE.
The filing also discloses recent trading activity by the Yeaman Family Trust, which sold:
- 25,000 shares for gross proceeds of $1,905,650 on June 10, 2025
- 8,683 shares for gross proceeds of $661,829 on June 10, 2025
This Form 144 represents a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. The total shares to be sold represent approximately 0.026% of Dolby's outstanding shares (96,066,188 shares).